Form 4: Danimer Scientific Executive Granted Stock Appreciation Rights and Performance Stock Award

Scott Tuten, Chief Marketing Officer of Danimer Scientific, received stock appreciation rights and a performance stock award on April 3, 2024, under the company's 2020 Long-Term Incentive Plan.

Summary

• On April 3, 2024, Scott Tuten, the Chief Marketing Officer of Danimer Scientific, was granted stock appreciation rights (SARs) for 263,410 shares and a performance stock award (PSA) for 151,585 shares under the company's 2020 Long-Term Incentive Plan.
• The SARs will vest in three tranches: 87,803 shares on each of April 3, 2025, and April 3, 2026, and 87,804 shares on April 3, 2027.
• The PSA's vesting is contingent upon achieving Total PHA Revenue and Adjusted EBITDA targets by December 31, 2026.
• 50% of the PSA (Total PHA Revenue Metric Shares) will vest based on Total PHA Revenue, with 50% vesting at $135 million and 100% vesting at $157 million, with pro-rata vesting in between.
• The other 50% of the PSA (Adjusted EBITDA Metric Shares) will vest based on Adjusted EBITDA, with 50% vesting at $17.2 million and 100% vesting at $22.3 million, with pro-rata vesting in between.
• The PSA will vest no later than April 3, 2027, or the Reporting Person's Termination Date.

Sentiment

Score: 7

Explanation: The document is neutral in tone, simply reporting the grant of stock options and performance awards. The positive aspect is the alignment of executive incentives with company performance, while the risk lies in the uncertainty of achieving the performance targets.

Positives

• The grants of SARs and PSAs align executive compensation with the company's long-term performance goals.
• The vesting criteria for the PSA are tied to specific revenue and profitability targets, incentivizing management to drive growth and efficiency.
• The long-term vesting schedule of the SARs encourages continued service and commitment from the executive.

Risks

• The PSA's vesting is contingent on achieving ambitious financial targets, and failure to meet these targets could result in the executive not receiving the full award.
• The value of the SARs is dependent on the future stock price of Danimer Scientific, which is subject to market fluctuations and company-specific risks.

Future Outlook

The vesting of the performance stock award is contingent upon Danimer Scientific achieving specific Total PHA Revenue and Adjusted EBITDA targets by the end of fiscal year 2026.

Industry Context

This announcement reflects a common practice in the industry to incentivize executives with equity-based compensation tied to company performance. The specific metrics used (PHA Revenue and Adjusted EBITDA) are relevant to Danimer Scientific's business model and growth strategy.

Comparison to Industry Standards

• Comparing Danimer Scientific's executive compensation structure to peers like Novozymes or Corbion, it's evident that performance-based equity awards are a standard practice.
• However, the specific metrics and targets may vary depending on the company's strategic priorities and stage of development.
• For instance, a more established company might focus on profitability metrics like net income, while a growth-oriented company like Danimer Scientific emphasizes revenue growth and adjusted EBITDA.
• The vesting schedules and performance thresholds also need to be benchmarked against industry averages to ensure competitiveness and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value creation.
• Employees: The grants may boost employee morale by demonstrating the company's commitment to its leadership team.

Key Dates

Keywords

Danimer Scientific, Stock Appreciation Rights, Performance Stock Award, Executive Compensation, PHA Revenue, Adjusted EBITDA, Scott Tuten, DNMR